Skip to main content
Top
Published in: Clinical Journal of Gastroenterology 1/2022

01-02-2022 | Enterohemorrhagic Escherichia Coli | Case Report

A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy

Authors: June Tome, Daniel Barry Maselli, Roeun Im, Matthew Brian Amdahl, Daniel Pfeifle, Catherine Hagen, Magnus Halland

Published in: Clinical Journal of Gastroenterology | Issue 1/2022

Login to get access

Abstract

The majority of cases of Shiga toxin-producing Escherichia coli are self-limited; however, the infection can occasionally be complicated by more severe phenomena, such as thrombotic microangiopathy, with resultant end-organ damage to the kidneys, colon, nervous system, and various other tissues. Shiga toxin-induced hemolytic uremic syndrome (ST-HUS)—the constellation of thrombocytopenia, hemolysis, and renal failure resulting from thrombotic microangiopathy in a subset of infections producing the Shiga toxin—is classically observed in the pediatric population. Nevertheless, the diagnosis should be considered in adults with this presentation, and especially in those with colonic findings suggestive of ischemia. ST-HUS must also be distinguished from other thrombotic microangiopathies and related conditions, such as disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and complement-mediated HUS, as these diagnoses prompt alternate management strategies. Here, we present a case of ST-HUS in a gentleman following pericardiectomy who was infected with non-O157:H7 E. coli producing Shiga toxin 2.
Literature
1.
go back to reference Brandt LJ, Feuerstadt P, Longstreth GF, et al. American College of Gastroenterology. ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol. 2015;110:18–44.CrossRef Brandt LJ, Feuerstadt P, Longstreth GF, et al. American College of Gastroenterology. ACG clinical guideline: epidemiology, risk factors, patterns of presentation, diagnosis, and management of colon ischemia (CI). Am J Gastroenterol. 2015;110:18–44.CrossRef
2.
go back to reference Valilis E, Ramsey A, Sidiq S, et al. Non-O157 Shiga toxin-producing Escherichia coli-A poorly appreciated enteric pathogen: systematic review. Int J Infect Dis. 2018;76:82–7.CrossRef Valilis E, Ramsey A, Sidiq S, et al. Non-O157 Shiga toxin-producing Escherichia coli-A poorly appreciated enteric pathogen: systematic review. Int J Infect Dis. 2018;76:82–7.CrossRef
3.
go back to reference Newell DG, La Ragione RM. Enterohaemorrhagic and other Shiga toxin-producing Escherichia coli (STEC): Where are we now regarding diagnostics and control strategies? Transbound Emerg Dis. 2018;65:49–71.CrossRef Newell DG, La Ragione RM. Enterohaemorrhagic and other Shiga toxin-producing Escherichia coli (STEC): Where are we now regarding diagnostics and control strategies? Transbound Emerg Dis. 2018;65:49–71.CrossRef
4.
go back to reference Bruyand M, Mariani-Kurkdjian P, Gouali M, et al. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect. 2018;48:167–74.CrossRef Bruyand M, Mariani-Kurkdjian P, Gouali M, et al. Hemolytic uremic syndrome due to Shiga toxin-producing Escherichia coli infection. Med Mal Infect. 2018;48:167–74.CrossRef
5.
go back to reference Frisema I, Van der Zwaluw K, Schuurman T, et al. Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin-producing E. coli (STEC) infections in the Netherlands, January 2008 to December 2011. Euro Surveill. 2014;19:20787. Frisema I, Van der Zwaluw K, Schuurman T, et al. Emergence of Escherichia coli encoding Shiga toxin 2f in human Shiga toxin-producing E. coli (STEC) infections in the Netherlands, January 2008 to December 2011. Euro Surveill. 2014;19:20787.
6.
go back to reference Joseph A, Cointe A, Kurkdjian PM, et al. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins. 2020;12:67.CrossRef Joseph A, Cointe A, Kurkdjian PM, et al. Shiga toxin-associated hemolytic uremic syndrome: a narrative review. Toxins. 2020;12:67.CrossRef
7.
go back to reference Melton-Celsa A, Mohawk K, Teel L, et al. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr Top Microbiol Immunol. 2012;357:67–103.PubMed Melton-Celsa A, Mohawk K, Teel L, et al. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr Top Microbiol Immunol. 2012;357:67–103.PubMed
8.
go back to reference Manrique-Caballero CL, Peerapornratana S, Formeck C, et al. Typical and atypical hemolytic uremic syndrome in the critically ill. Crit Care Clin. 2020;36:333–56.CrossRef Manrique-Caballero CL, Peerapornratana S, Formeck C, et al. Typical and atypical hemolytic uremic syndrome in the critically ill. Crit Care Clin. 2020;36:333–56.CrossRef
9.
go back to reference Hunt JM. Shiga toxin-producing Escherichia coli. Clin Lab Med. 2010;30:21–45.CrossRef Hunt JM. Shiga toxin-producing Escherichia coli. Clin Lab Med. 2010;30:21–45.CrossRef
10.
go back to reference Rahman RC, Cobeñas CJ, Drut R, et al. Hemorrhagic colitis in post diarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol. 2012;27:229–33.CrossRef Rahman RC, Cobeñas CJ, Drut R, et al. Hemorrhagic colitis in post diarrheal hemolytic uremic syndrome: retrospective analysis of 54 children. Pediatr Nephrol. 2012;27:229–33.CrossRef
11.
go back to reference Buelli S, Zoja C, Remuzzi G, et al. Complement activation contributes to the pathophysiology of shiga toxin-associated hemolytic uremic syndrome. Microorganisms. 2019;7:15.CrossRef Buelli S, Zoja C, Remuzzi G, et al. Complement activation contributes to the pathophysiology of shiga toxin-associated hemolytic uremic syndrome. Microorganisms. 2019;7:15.CrossRef
12.
go back to reference Trachtman H, Austin C, Lewinski M, et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012;8:658–69.CrossRef Trachtman H, Austin C, Lewinski M, et al. Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol. 2012;8:658–69.CrossRef
13.
go back to reference Balestracci A, Martin SM, Toledo I, et al. Laboratory predictors of acute dialysis in hemolytic uremic syndrome. Pediatr Int. 2014;56:234–9.CrossRef Balestracci A, Martin SM, Toledo I, et al. Laboratory predictors of acute dialysis in hemolytic uremic syndrome. Pediatr Int. 2014;56:234–9.CrossRef
14.
go back to reference Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218–28.CrossRef Nathanson S, Kwon T, Elmaleh M, et al. Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2010;5:1218–28.CrossRef
15.
go back to reference Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol. 2019;34:2495–507.CrossRef Khalid M, Andreoli S. Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol. 2019;34:2495–507.CrossRef
16.
go back to reference Farooq PD, Urrunaga NH, Tang DM, et al. Pseudomembranous colitis. Dis Mon. 2015;61:181–206.CrossRef Farooq PD, Urrunaga NH, Tang DM, et al. Pseudomembranous colitis. Dis Mon. 2015;61:181–206.CrossRef
17.
go back to reference Jessurun J. The differential diagnosis of acute colitis: clues to a specific diagnosis. Surg Pathol Clin. 2017;10:863–85.CrossRef Jessurun J. The differential diagnosis of acute colitis: clues to a specific diagnosis. Surg Pathol Clin. 2017;10:863–85.CrossRef
18.
go back to reference Bannas P, Fraedrich K, Treszl A, et al. Shiga toxin-producing E. coli O104:H4 outbreak 2011 in Germany: radiological features of enterohemorrhagic colitis. Rofo. 2013;185:434–9.CrossRef Bannas P, Fraedrich K, Treszl A, et al. Shiga toxin-producing E. coli O104:H4 outbreak 2011 in Germany: radiological features of enterohemorrhagic colitis. Rofo. 2013;185:434–9.CrossRef
19.
go back to reference Grisaru S, Xie S, Samuel S, et al. Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin–producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr. 2017;171:68.CrossRef Grisaru S, Xie S, Samuel S, et al. Associations between hydration status, intravenous fluid administration, and outcomes of patients infected with Shiga toxin–producing Escherichia coli: a systematic review and meta-analysis. JAMA Pediatr. 2017;171:68.CrossRef
20.
go back to reference Freedman SB, Xie J, Neufeld MS, et al. Shiga toxin–producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis. 2016;62:1251–8.CrossRef Freedman SB, Xie J, Neufeld MS, et al. Shiga toxin–producing Escherichia coli infection, antibiotics, and risk of developing hemolytic uremic syndrome: a meta-analysis. Clin Infect Dis. 2016;62:1251–8.CrossRef
21.
go back to reference Ninchoji T, Nozu K, Nakanishi K, et al. Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience. Clin Exp Nephrol. 2017;21:889–94.CrossRef Ninchoji T, Nozu K, Nakanishi K, et al. Clinical characteristics and long-term outcome of diarrhea-associated hemolytic uremic syndrome: a single center experience. Clin Exp Nephrol. 2017;21:889–94.CrossRef
22.
go back to reference Harkins VJ, McAllister DA, Reynolds BC. Shiga-toxin E. coli hemolytic uremic syndrome: review of management and long-term outcome. Curr Pediatr Rep. 2020;8:16–25.CrossRef Harkins VJ, McAllister DA, Reynolds BC. Shiga-toxin E. coli hemolytic uremic syndrome: review of management and long-term outcome. Curr Pediatr Rep. 2020;8:16–25.CrossRef
23.
go back to reference Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.CrossRef Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.CrossRef
24.
go back to reference Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364:2561–3.CrossRef Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med. 2011;364:2561–3.CrossRef
25.
go back to reference Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000–2006. Clin Infect Dis. 2009;49:1480–5.CrossRef Gould LH, Demma L, Jones TF, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000–2006. Clin Infect Dis. 2009;49:1480–5.CrossRef
26.
go back to reference Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis. 2012;54:1413–21.CrossRef Rosales A, Hofer J, Zimmerhackl LB, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis. 2012;54:1413–21.CrossRef
27.
go back to reference Gould LH, Mody RK, Ong KL, et al. Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: Epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis. 2013;10:453–60.CrossRef Gould LH, Mody RK, Ong KL, et al. Increased recognition of non-O157 Shiga toxin-producing Escherichia coli infections in the United States during 2000–2010: Epidemiologic features and comparison with E. coli O157 infections. Foodborne Pathog Dis. 2013;10:453–60.CrossRef
28.
go back to reference Braune SA, Wichmann D, Von Heinz MC, et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med. 2013;41:1702–10.CrossRef Braune SA, Wichmann D, Von Heinz MC, et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med. 2013;41:1702–10.CrossRef
Metadata
Title
A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy
Authors
June Tome
Daniel Barry Maselli
Roeun Im
Matthew Brian Amdahl
Daniel Pfeifle
Catherine Hagen
Magnus Halland
Publication date
01-02-2022
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 1/2022
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-021-01539-8

Other articles of this Issue 1/2022

Clinical Journal of Gastroenterology 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine